Variantes del SARS-CoV-2 Neutralizadas Por Nanocuerpos de Camellos .

 Los Nanocuerpos de Camellos Exhiben Potentes Capacidades de Neutralización Contra las Variantes B.1.351 y B.1.1.7  .

Investigadores de los EE. UU. Aislaron recientemente dos nanocuerpos V H H, 7A3 y 8A2, de camellos dromedarios ( Camelus dromedaries ) mediante la visualización de fagos. Se descubrió que estos nanocuerpos tienen una alta afinidad por el pico RBD y una amplia capacidad de neutralización contra el SARS-CoV-2 y sus variantes. 

Este estudio está disponible actualmente en el servidor de preimpresión medRxiv * mientras espera la revisión por pares.

Los anticuerpos de dominio único VHH de camélidos son capaces de reconocer cavidades proteicas a las que los anticuerpos convencionales no pueden acceder debido a su pequeño tamaño y conformaciones peculiares.

El presente estudio desarrolló nuevas bibliotecas de fagos de anticuerpos de dominio único VHH de camello de seis camellos dromedarios. Utilizaron el RBD de pico de SARS-CoV-2 y la proteína trímero de ectodominio de pico como cebos mientras realizaban un cribado de fagos para detectar nanocuerpos.

Los Anticuerpos de dominio único como NCI-CoV-7A3 (7A3), NCI-CoV-1B5 (1B5), NCI-CoV-8A2 (8A2) y NCI-CoV-2F7 (2F7) son fuertes bloqueadores de ACE2. Estos nanocuerpos también exhiben potentes capacidades de neutralización contra las variantes B.1.351 y B.1.1.7 y la cepa original del SARS-CoV-2, Wuhan-Hu-1. ...

LAGEVRIO ( Molnupiravir ) // COVID19 // MERCK // UK . Los Reguladores del Reino Unido Aprueban la Primera Píldora del Mundo Para Tratar el COVID19 Que se Puede Tomar en Casa . También Ha Recibido el Aval de la EMA ( Agencia Europea del Medicamento ) .

Las Autoridades Sanitarias del Reino Unido Han Dado el Visto Bueno a la Pastilla Antiviral Lagevrio ( Molnupiravir ), desarrollada Por las Compañías Estadounidenses Merck, Sharp and Dohme (MSD) y Ridgeback Biotherapeutics. 

Poco Después, la EMA (Agencia Europea del Medicamento) Avaló el Uso de Emergencia del Antiviral . 

Así lo Anunció Marco Cavaleri, Responsable de Productos Biológicos y Estrategia Vacunal .

COVID19 . Cambio en las Reglas de Juego Para los Más Vulnerables y los Inmunosuprimidos, Que Pronto Podrán Recibir el Tratamiento Innovador .

Hoy es un Día Histórico Para Nuestro País, Ya Que el Reino Unido es Ahora el Primer País del Mundo en Aprobar un Antiviral Que se Puede Tomar en Casa Para el COVID19 .

TRATAMIENTO ORAL COVID19 ... PFIZER NO VA A DEJAR SOLA A MERCK CON EL PASTEL Y TAMBIÉN ESTA A UN PASO DEL MERCADO . PFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY .

 

Friday, November 05, 2021 .

• PAXLOVID™ (PF-07321332; ritonavir) was found to reduce the risk of hospitalization or death by 89% compared to placebo in non-hospitalized high-risk adults with COVID-19
• In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 deaths in patients who received placebo
• Pfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible .

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced its investigational novel COVID-19 oral antiviral candidate,PAXLOVID™, significantly reduced hospitalization and death, based on an interim analysis of the Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. 

The scheduled interim analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint); 0.8% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (3/389 hospitalized with no deaths), compared to 7.0% of patients who received placebo and were hospitalized or died (27/385 hospitalized with 7 subsequent deaths).

 

The statistical significance of these results was high (p<0.0001). 

Similar reductions in COVID-19-related hospitalization or death were observed in patients treated within five days of symptom onset; 1.0% of patients who received PAXLOVID™ were hospitalized through Day 28 following randomization (6/607 hospitalized, with no deaths), compared to 6.7% of patients who received a placebo (41/612 hospitalized with 10 subsequent deaths), with high statistical significance (p<0.0001). 

In the overall study population through Day 28, no deaths were reported in patients who received PAXLOVID™ as compared to 10 (1.6%) deaths in patients who received placebo. ...

EEUU . Grifols Introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% Concentrations, a More Convenient Option For Healthcare Professionals .

- The ALBUTEIN FlexBag, Now Available in The U.S., Comes in Several Sizes : 250 mL and 500 mL Bags For 5%, and 50 mL and 100 mL Bags for 25% .

- Grifols is the Only Manufacturer To Offer a 500 mL 5% Albumin Option For Customers in an Easy-To-Use, Flexible Container .

- It is Provided in an Environmentally Friendly Bag, Free of Plasticizers, Offering Healthcare Professionals a More Sustainable Choice .

BARCELONA, Spain, Nov. 4, 2021 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading Global Producer of Plasma-derived Medicines, Today Announced the Launch of its Latest Albumin Portfolio Innovation, ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% Concentrations . ...